Genentech: Avastin boosts chances of progression-free survival among ovarian cancer patients
SOUTH SAN FRANCISCO, Calif. — Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.
Genentech, part of Swiss drug maker Roche, announced results from its phase-3 “OCEANS” study, in which women with recurring ovarian cancer received Avastin (bevacizumab) with gemcitabine and carboplatin, both chemotherapy drugs, followed by use of Avastin alone.
The study found that the women who received Avastin had better chances of progression-free survival than women who only received chemotherapy.
Avastin has Food and Drug Administration approval for treating colorectal, lung and kidney cancers.